One specific study (NCT01550523) assessed glioma cell–derived exosomes that were engineered to carry an antisense molecule against the insulin-like growth factor I receptor (IGF1R), demonstrating both the feasibility and safety of exosome-based therapeutic delivery (161). Here, IGF1R is linked to glioma.